This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Rubbert A, Kielhorn A, Schach S, Brown B, Aristides M.Cost-effectiveness of rituximab as a new treatment modality for rheumatoid arthritis in Germany. Value in Health 9: 25 (plus poster) abstr. PAR5, No. 3, May-Jun 2006
De Vita S, Giuliani G, Diamantopoulos A, Brown B, Kielhorn A.Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy. Value in Health 9: 26 (plus poster) abstr. PAR7, No. 3, May-Jun 2006
Kielhorn A, Alvarez C, Aristides M, Diamantopoulos A.Using MabThera in patients with rheumatic arthritis in Spain: results of cost-effectiveness data based on micro-simulation. Value in Health 9: 26 (plus poster) abstr. PAR8, No. 3, May-Jun 2006
Porter D, Lewis G, Brown B, Diamantopoulos A, Kielhorn A.Cost-effectiveness analysis of rituximab as a new therapeutic option for rheumatoid arthritis in the UK. Value in Health 9: 25, No. 3, May-Jun 2006
Kielhorn A, Rubbert A, Porter D, De Vita S, Brown B, Aristides M, Aultman R, Jost F.Cost-effectiveness of rituximab therapy for rheumatoid arthritis: a pan-European analysis. Value in Health 9: 27 (plus poster) abstr. PAR10, No. 3, May-Jun 2006
Rights and permissions
About this article
Cite this article
Rituximab gives standard RA therapies a run for their money. Pharmacoecon. Outcomes News 507, 3–4 (2006). https://doi.org/10.2165/00151234-200605070-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605070-00004